VB50 Stock Overview
A biopharmaceutical drug discovery company, researches and develops drugs for psychedelic-assisted therapy for patients with urgent and unmet needs in Canada and the United Kingdom. More details
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 0/6 |
| Dividends | 0/6 |
Albert Labs International Corp. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | CA$0.005 |
| 52 Week High | CA$0.016 |
| 52 Week Low | CA$0.0015 |
| Beta | 3.13 |
| 11 Month Change | 0% |
| 3 Month Change | 0% |
| 1 Year Change | -50.00% |
| 33 Year Change | n/a |
| 5 Year Change | n/a |
| Change since IPO | -94.44% |
Recent News & Updates
Recent updates
Shareholder Returns
| VB50 | DE Biotechs | DE Market | |
|---|---|---|---|
| 7D | 0% | -0.7% | -0.02% |
| 1Y | -50.0% | -17.2% | 8.2% |
Return vs Industry: VB50 underperformed the German Biotechs industry which returned -12.1% over the past year.
Return vs Market: VB50 underperformed the German Market which returned 14% over the past year.
Price Volatility
| VB50 volatility | |
|---|---|
| VB50 Average Weekly Movement | n/a |
| Biotechs Industry Average Movement | 6.5% |
| Market Average Movement | 4.8% |
| 10% most volatile stocks in DE Market | 10.9% |
| 10% least volatile stocks in DE Market | 2.3% |
Stable Share Price: VB50's share price has been volatile over the past 3 months compared to the German market.
Volatility Over Time: Insufficient data to determine VB50's volatility change over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| n/a | n/a | Chand Jagpal | albertlabs.com |
Albert Labs International Corp., a biopharmaceutical drug discovery company, researches and develops drugs for psychedelic-assisted therapy for patients with urgent and unmet needs in Canada and the United Kingdom. It develops KRN-101, is a solution for cancer-related anxiety. The company is based in Burnaby, Canada.
Albert Labs International Corp. Fundamentals Summary
| VB50 fundamental statistics | |
|---|---|
| Market cap | €247.24k |
| Earnings (TTM) | -€1.53m |
| Revenue (TTM) | n/a |
0.0x
P/S Ratio-0.2x
P/E RatioIs VB50 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| VB50 income statement (TTM) | |
|---|---|
| Revenue | CA$0 |
| Cost of Revenue | CA$0 |
| Gross Profit | CA$0 |
| Other Expenses | CA$2.31m |
| Earnings | -CA$2.31m |
Last Reported Earnings
Sep 30, 2023
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.031 |
| Gross Margin | 0.00% |
| Net Profit Margin | 0.00% |
| Debt/Equity Ratio | -2.3% |
How did VB50 perform over the long term?
See historical performance and comparison